Research map: FGF/FGFR Alteration Type as a Candidate Enrichment Biomarker for Gunagratinib in Recurrent or Metastatic Head and Neck Cancer: An Exploratory Analysis of Two Early-Phase Trials

Back to the article

Papers in this map

  1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries · Freddie Bray · 2024 · 26051 citations · Cited by this paper
  2. Cardiotoxicity Profiles of Osimertinib Compared with Other EGFR Tyrosine Kinase Inhibitors: A Real-World Comparative Incidence Analysis · 2025 · Related
  3. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck · Robert Louis Ferris · 2016 · 5197 citations · Cited by this paper
  4. Age-Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors: A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer · 2026 · Related
  5. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study · Barbara Ann Burtness · 2019 · 3349 citations · Cited by this paper
  6. MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies · 2025 · Related
  7. Cancer incidence and mortality in China, 2022 · Bingfeng Han · 2024 · 2241 citations · Cited by this paper
  8. Targeting DNA Damage Repair Pathways Beyond PARP Inhibition · 2025 · Related
  9. Head and neck cancer · Mayur D. Mody · 2021 · 875 citations · Cited by this paper
  10. Real-World Treatment Patterns in Advanced Cutaneous Melanoma in the USA · 2026 · Related
  11. Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas · Tanguy Y. Seiwert · 2014 · 670 citations · Cited by this paper
  12. Bispecific Antibodies in Breast Cancer Immunotherapy: Mechanisms, Advances, and Translational Challenges · 2026 · Related
  13. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma · Chen Lu Huang · 2021 · 392 citations · Cited by this paper
  14. Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer · 2026 · Related
  15. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study) · Kwok‐Hung Au · 2017 · 297 citations · Cited by this paper
  16. Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma? · 2026 · Related
  17. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma · Hai‐Qiang Mai · 2023 · 275 citations · Cited by this paper
  18. Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study) · 2026 · Related
  19. Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study · Funda Meric‐Bernstam · 2021 · 262 citations · Cited by this paper
  20. Recent highlights and breakthroughs in immunotherapy for head and neck cancers · 2026 · Related
  21. Targeted therapy for head and neck cancer: signaling pathways and clinical studies · Qingfang Li · 2023 · 257 citations · Cited by this paper
  22. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study · Shubham Pant · 2023 · 216 citations · Cited by this paper
  23. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies · Vivek Subbiah · 2022 · 204 citations · Cited by this paper
  24. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions · Masuko Katoh · 2024 · 194 citations · Cited by this paper
  25. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study · Martin Schüler · 2019 · 181 citations · Cited by this paper
  26. FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice · Anuhya Kommalapati · 2021 · 155 citations · Cited by this paper
  27. Activation of the FGFR1 signalling pathway by the Epstein–Barr virus‐encoded LMP1 promotes aerobic glycolysis and transformation of human nasopharyngeal epithelial cells · Angela Kwok‐Fung Lo · 2015 · 133 citations · Cited by this paper
  28. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma · Yuan Li · 2014 · 108 citations · Cited by this paper
  29. EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma · Qibiao Wu · 2022 · 105 citations · Cited by this paper
  30. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma · Koos Koole · 2016 · 96 citations · Cited by this paper
  31. Head and Neck Cancer · Lara Ann Dunn · 2025 · 73 citations · Cited by this paper
  32. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival · Coraline Dubot · 2018 · 70 citations · Cited by this paper
  33. Clinical development and management of adverse events associated with FGFR inhibitors · Vivek Subbiah · 2023 · 68 citations · Cited by this paper
  34. Global burden of head and neck cancer: Epidemiological transitions, inequities, and projections to 2050 · Haowei Sun · 2025 · 59 citations · Cited by this paper
  35. Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer · Mei Lin Peng · 2024 · 51 citations · Cited by this paper
  36. Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma · Michihisa Kono · 2022 · 39 citations · Cited by this paper
  37. Fibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review · Norbertus Anton Ipenburg · 2015 · 36 citations · Cited by this paper
  38. Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer · Zechen Wang · 2022 · 36 citations · Cited by this paper
  39. Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor–Associated Retinopathy · Jasmine H. Francis · 2021 · 31 citations · Cited by this paper

Source: OpenAlex (CC0)